Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its ...
The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) are trading higher Friday after the U.S. Food and Drug Administration announced plans to phase out its requirement for animal testing in favor ...
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data ...
HC Wainwright reiterated their buy rating on shares of Absci (NASDAQ:ABSI – Free Report) in a research report report published on Wednesday,Benzinga reports. They currently have a $7.00 price target ...
Absci (NASDAQ:ABSI – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Guggenheim in a research note issued to investors on Thursday,Benzinga reports. They presently have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results